| This week's sponsor is FierceBiotech. | |  | |
Today's Rundown Featured Story | | | Thursday, January 3, 2019 Ex-Novartis Oncology CEO Liz Barrett has joined UroGen Pharma. Barrett is taking over as CEO of the uro-oncology specialist at a time when it is working on a rolling NDA that could lead to its first drug approval. |
|
|
Top Stories Thursday, January 3, 2019 The long-predicted deal-making boom in Big Pharma started with a bang on Wednesday, as Bristol-Myers Squibb announced it will buy Celgene in a cash and stock transaction worth $74 billion. The deal values Celgene at $102.43 a share—54% higher than its closing price on Tuesday evening. Thursday, January 3, 2019 Just over a year after its first-round financing, CRISPR company Locus Biosciences has signed up Johnson & Johnson as its first big pharma partner and pocketed a $20 million upfront fee. Thursday, January 3, 2019 Merck has acquired the exclusive global rights to NGM Biopharmaceuticals’ treatment for NASH and Type 2 diabetes. The agreement gives Merck control of a drug designed to reduce liver fat content by selectively activating FGFR1c. Thursday, January 3, 2019 Lucia Septién-Velez has stepped down as CMO of DBV Technologies. The departure of Septién-Velez is part of a wider reshuffle that gives DBV’s management a new look as it seeks to get its BLA back on track. Thursday, January 3, 2019 Drug accelerator Cydan unveiled its third orphan drug company: Tiburio Therapeutics, which starts life with $31 million in series A funding and a pair of clinical-stage compounds licensed from Ipsen. Thursday, January 3, 2019 TwoXAR has inked its third drug discovery partnership, this one with South Korea’s 1ST Biotherapeutics. Under the deal, twoXAR will identify drug candidates using its artificial intelligence platform, both partners will select promising candidates and 1ST Bio will develop them. Thursday, January 3, 2019 Otsuka will “commit capital to fully fund” the development of Click’s mobile application, dubbed CT-152, for major depressive disorder and to market the app worldwide. Wednesday, January 2, 2019 French Big Pharma Sanofi is walking away from a heart drug disease pact with MyoKardia ahead of data readouts coming later this year. Resources Presented by: Aprecia Get ahead of looming challenges in the market that include both generic products and new branded drugs. Sponsored by: Oracle Health Sciences New infographic shows trends in clinical development and the impact on randomization and trial supply management technology (RTSM). Sponsored by: Veeva Reduce the effort to create submissions and track registrations with a move to unified RIM. Watch the on-demand webinar. Sponsored by: DocuSign Life sciences companies must immediately identify and realize productivity gains to drive down operational costs—or risk seeing more nimble competitors disappear into the distance. Where to begin? Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
